GlassScriptPhysician profile
Michelle L Dees
NPI 1871648642
$288,524.56
in general payments reported to CMS, 2019-2025
25 companies · $599 in 2025
The $599 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $32K · 2021: $44K · 2022: $50K · 2023: $51K · 2024: $37K · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Travel and Lodging: $16K · Food and Beverage: $3,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,931.50 |
| Travel and Lodging | $15,985.67 |
| Food and Beverage | $3,033.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66,313.78 | 2020-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $65,497.05 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $51,024.40 | 2019-2025 | Nuedexta, Rexulti |
| Teva Pharmaceuticals USA, INC. | $46,393.93 | 2019-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $18,713.97 | 2019-2024 | Lybalvi |
| Allergan, INC. | $18,711.88 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $10,343.39 | 2019-2022 | |
| Abbvie INC. | $8,135.18 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $1,093.41 | 2019-2025 | Spravato |
| Neuronetics, INC. | $893.17 | 2019-2024 | Neurostar Tms Therapy System |
| Neurocrine Biosciences, INC. | $453.11 | 2019-2021 | |
| Axsome Therapeutics, INC. | $307.38 | 2023-2025 | Auvelity |
| Bioxcel Therapeutics, INC. | $135.80 | 2023 | Igalmi |
| Brainsway USA INC | $111.44 | 2019 | |
| Tris Pharma INC | $99.79 | 2024-2025 | Dyanavel Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $70.97 | 2022-2023 | Trintellix, Takhzyro |
| Lundbeck LLC | $54.77 | 2022-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $32.34 | 2025 | Cobenfy |
| Galderma Laboratories, L.P. | $26.87 | 2021 | |
| Vanda Pharmaceuticals INC. | $21.56 | 2021 | |
| Merck Sharp & Dohme LLC | $19.67 | 2021 | |
| Almatica Pharma LLC | $18.18 | 2024 | Loreev Xr |
| Lilly USA, LLC | $18.10 | 2025 | Zepbound |
| Supernus Pharmaceuticals, INC. | $17.44 | 2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $16.98 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Dees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.